Innovation by SurgeonTissue engineering: From bench to bedside via commercialization
Section snippets
Laboratory history of tissue engineering and corporate involvement
While a young assistant professor of surgery at Children's Hospital Boston and Harvard Medical School in 1985, I came to the realization that the organ shortage would be my biggest problem in pediatric liver transplantation and that it was a specific manifestation of the general problem in all areas of reconstructive surgery—the lack of sufficient tissue for reconstruction. Based on my years of work with Dr Judah Folkman and his seminal observations in angiogenesis, I developed the idea of
Conflict of interest and other issues related to the interface of academia and industry
Conflict of interest guidelines have become an important safeguard to keep the welfare of the patient as the top priority for the introduction of any new technology. Harvard, MIT, and MGH have very similar guidelines in this regard. In clinical research, physicians cannot be responsible for clinical trials and cannot have any financial interest in the corporate entities that can derive financial benefit from the successful introduction of a technology. These principles ensure a clear separation
References (0)
Cited by (14)
Commercialization and regulation of regenerative medicine products: Promises, advances and challenges
2022, Biomedicine and PharmacotherapyCitation Excerpt :For example, industry often complains that working with Universities slows down commercialization and there is still a general feeling (although decreasing) that academics should not be working with industry (specifically, for-profit entities) with proprietary needs. To create the optimal regenerative medicine industry, concepts (such as determining the purpose of research, providing research tools, in vivo evaluation of products, and their clinical performance) should be done in direct cooperation with industry and academia [51]. As shown in Table 4, the number of TE companies, especially in the US, is growing [52].
Fetal Tissue Engineering
2009, Clinics in PerinatologyCitation Excerpt :Indeed, many firms driven by an initial substantial interest in tissue engineering have exited the market over the last 5 to 10 years. Still, dozens of companies continue to invest in the development of new products.92,93 It seems that a healthy partnership between academia and industry should be the best option to further expand tissue engineering into clinical reality, a principle that appears to be particularly relevant to fetal tissue engineering, given its sources purely in academia and its sizeable target market, not to mention the perspective of prolonged fetal cell banking.
Translation to success of surgical innovation
2010, European Journal of Cardio-thoracic SurgeryTissue engineering and regenerative therapeutics: The nexus of chemical engineering and translational medicine
2021, Canadian Journal of Chemical EngineeringResearch in pediatric surgery
2018, Rickham's neonatal surgery